Navigation Links
Advanced Pain Remedies, a Subsidiary of Cato BioVentures, Announces a Three Million Dollar Award from the National Cancer Institute for SP-SAP
Date:1/10/2011

DURHAM, N.C., Jan. 10, 2011 /PRNewswire/ -- Advanced Pain Remedies (APR), a subsidiary of Cato BioVentures, announces that a three million dollar grant has been received, to advance its lead development candidate, SP-SAP. Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases, has been awarded a $3 million grant from the National Cancer Institute (NCI). Advanced Targeting Systems, working with APR, will use these funds to advance the technology over the next three years to initiate the clinical program for SP-SAP in end-stage cancer patients with intractable pain.

SP-SAP is a conjugate of the pain-processing peptide Substance P and the ribosomal inactivating protein saporin. The mechanism of action is well characterized. A small number of cells that process pathological pain signals are inactivated causing pain relief that appears to be permanent, whereas, normal acute pain is unaffected. In preclinical tests, a single treatment with SP-SAP alleviated pathologic pain perception without affecting other sensory signal pathways.

Following discussions and input from the Food and Drug Administration (FDA), the first population to undergo treatment with SP-SAP will be terminal cancer patients. There is an unmet medical need in this population and a desire to find a treatment that would allow patients an alternative to opioids for pain relief as they are nearing the end of their lives. APR, partnered with Cato Research, a global contract research and development organization (CRO), will lead the regulatory and development aspects of this project.

"I am pleased that the National Cancer Institute has recognized the importance of this project.  With their assistance, we will be able to move this promising technology into clinical trials and determine its potential benefit to this patient population," stated Dr. Allen Cato, CEO of Advanced Pain Remedies and Cato
'/>"/>

SOURCE Advanced Pain Remedies; Cato BioVentures
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
2. Advanced Life Sciences Announces Second Quarter 2008 Financial Results
3. LUMEDX Introduces Advanced Multi-Modality, Multi-Vendor, Web-Enabled ECG Management Solution
4. Waters Brings Advanced Laboratory Data Management to Microsofts BioIT Alliance
5. Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
6. Advanced Pest Control Earns Quality Pro Designation for General Pest Control Services
7. Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
8. Advanced Chemical Transport Opens Merced Facility
9. Advanced Life Sciences to Host Conference Call to Update Investors on Progress of Corporate Initiatives on October 1, 2008
10. Advanced Instruments Acquires D & F Control Systems Inc.
11. DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 High ... and apply the most complete climate and Earth ... demanding climate change issues. , Eight national laboratories, ... with the National Center for Atmospheric Research, four ... new effort. Other participating national laboratories include Argonne, ...
(Date:8/20/2014)...  PAREXEL International Corporation (NASDAQ: PRXL ) ... Baird Healthcare Conference in New York.  Ingo Bank ... be making a presentation on PAREXEL and discussing business ... 2014. A live webcast of the discussion ... website at www.PAREXEL.com in the Upcoming Events ...
(Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
(Date:8/20/2014)... health of your heart, researchers have discovered. , A ... TENS machine like those designed to relieve labour pains ... raised flap at the front of the ear immediately ... changed the influence of the nervous system on the ... failing hearts too hard. , Professor Jim Deuchars, Professor ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2
... uses Medical College of Wisconsin technologies and clinical and ... of diagnostics for sepsis and pneumonia. , ,The company, ... will come over the next five years, would enable ... methods, and demonstrate the performance of this new molecular ...
... Brady Corp., a Milwaukee-based identification, safety, graphic systems ... security software developer. , ,Brady did not disclose ... , of San Jose. , ,STOPware, founded in ... and track visitors in a variety of settings, including ...
... Madison, Wis. -- Dr. Carlos Perez has been ... Inc . in Madison. Perez is a former president ... more than 40 years of experience in radiation oncology. ... of Radiation Oncology at Mallinckrodt Institute of Radiology, Siteman ...
Cached Biology Technology:
(Date:8/21/2014)... North Carolina State University have developed a novel and ... has applications for creating new materials as well as ... new technique allows us to model much larger and ... more quickly," says Nan Li, lead author of a ... NC State,s Department of Materials Science and Engineering. "This ...
(Date:8/20/2014)... LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at ... forms of the gene that encodes BCR-ABL, the unregulated ... According to the American Cancer Society, nearly 6,000 new ... Drugs already in use, called tyrosine kinase inhibitors (TKIs), ... They do not cure CML but control it in ...
(Date:8/20/2014)... of the Para and Mato Grosso states of Brazil. ... in order to deforest the land. Deforestation is the ... the land is thereafter converted to a nonforest use. ... ranches, or urban use. The herringbone-patterned tan lines cutting ... the middle of the image are evidence of deforestation ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... The Field Museum announced today that it has received 409,416 ... of Monaco Foundation for a three-year project: Establishing new conservation ... biological inventories by The Field Museum,s Environment, Culture, and Conservation ... landscapes in Ecuador, Peru, and Bolivia. Eight of these areas ...
... CryoLife, Inc. (NYSE: CRY) Elite cardiovascular surgeons from around ... the two-day Ross Summit to review and discuss current peer-reviewed ... and to practice the technical nuances required to perform this ... type of specialized aortic valve surgery in which the patient,s ...
... Rush University Medical Center is participating in a ... to determine whether a vitamin-like substance, in high doses, ... disorder that affects about one million people in the ... we have for Parkinson,s can only mask the symptoms ...
Cached Biology News:Prince Albert II of Monaco Foundation helps fund Field Museum conservation efforts in Peru 2Growing outcomes evidence spurs renewed interest in unique heart valve procedure 2Can an over-the-counter vitamin-like substance slow the progression of Parkinson's disease? 2
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
Biology Products: